Research Article
Published: March 20, 2026 DOI: 10.33552/ACRCI.2026.05.000605
Abstract: Purpose: This Study Proposes A Novel Theranostic Approach Using Gallium-68 Chloride (⁶⁸GaCl₃) In Hydrochloric Acid (HCl) As A Potential Treatment For SARS-CoV-2, Aiming To Explore Viral Inactivation Through Targeted Delivery In Acidic Environments. Procedures: Drawing From Existing Literature On SARS-CoV-2 Susceptibility To Acidic Environments And The Chemical Properties Of Gallium-68, A Hypothesis Was Formulated. A Research Proposal Was Created To Administer 5 ML Of ⁶⁸Ga/0.1 M HCl To COVID-19 Patients For Five Days, Using PET Imaging For Verification Of Targeting. Results: A Pilot Investigation Was Conducted Whereby Two Patients With Moderate Pneumonia Received A Single Intravenous Dose Of 5 ML Of ⁶⁸Ga-DOTATATE In A 0.1 M HCl Medium. PET/CT Imaging Showed Notable Accumulation Of The ⁶⁸Ga/HCl Complex In The Lungs, Specifically In Areas Of Inflammation, Confirming Successful Delivery To Viral Replication Sites. Conclusions: The Pilot Study Supports The Viability Of The Theranostic Approach In Targeting SARS-CoV-2. This Narrative Emphasizes The Importance Of Innovative Thinking During Health Crises And Highlights The Potential Of Repurposing Diagnostic Radionuclides For Therapeutic Applications Against Emerging Viral Threats.
a Creative Commons Attribution 4.0 International License. Based on a work at www.irispublishers.com.
Best viewed in
| Above IE 9.0 version | Privacy Policy
